192508-36-4

Basic information

• Product Name: (4-FLUORO-3-NITROPHENYL)ACETIC ACID
• Synonyms: (4-FLUORO-3-NITROPHENYL)ACETIC ACID;3-nitro-4-fluorophenylacetic acid;2-(4-Fluoro-3-nitrophenyl)acetic acid;2-(4-Fluoro-3-nitrophenyl)
• CAS NO: 192508-36-4
• Molecular Formula: C₈H₆FNO₄
• Molecular Weight: 199.14
• Product Categories: Aromatic Phenylacetic Acids and Derivatives;Fluorine series
• Mol File: 192508-36-4.mol

Chemical Properties

• Boiling Point: 391.209°C at 760 mmHg
• Flash Point: 190.397°C
• Appearance: /
• Density: 1.498g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.575
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.01±0.10(Predicted)
• CAS DataBase Reference: (4-FLUORO-3-NITROPHENYL)ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (4-FLUORO-3-NITROPHENYL)ACETIC ACID(192508-36-4)
• EPA Substance Registry System: (4-FLUORO-3-NITROPHENYL)ACETIC ACID(192508-36-4)

Safety Data

• Hazardous Substances Data: 192508-36-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
(4-FLUORO-3-NITROPHENYL)ACETIC ACID is used as an intermediate in the synthesis of various biologically active compounds, including pharmaceuticals and agrochemicals. Its unique chemical structure and properties make it a valuable component in the development of new drugs with potential therapeutic applications.
Used in Medicinal Chemistry:
(4-FLUORO-3-NITROPHENYL)ACETIC ACID is utilized in medicinal chemistry for its potential pharmacological properties. Its chemical structure allows for further exploration and modification to enhance its therapeutic effects and target specific biological pathways.
Used in Anti-inflammatory and Analgesic Applications:
(4-FLUORO-3-NITROPHENYL)ACETIC ACID has been studied for its potential anti-inflammatory and analgesic properties. Its ability to modulate inflammatory responses and alleviate pain makes it a promising candidate for the development of new treatments for various inflammatory and pain-related conditions.

InChI:InChI=1/C8H6FNO4/c9-6-2-1-5(4-8(11)12)3-7(6)10(13)14/h1-3H,4H2,(H,11,12)

Upstream product

• 226888-37-5 4-fluoro-3-nitrophenylacetic acid methyl ester 
• 157662-77-6 2-(4-fluoro-3-nitrophenyl)acetonitrile 
• 405-50-5 p-Fluorophenylacetic acid 

Downstream Products

• 192508-37-5 <2-(4-fluoro-3-nitrophenyl)-acetylamino>-acetic acid methyl ester 
• 226888-23-9 2-<(2R)-2-(4-fluoro-3-nitrophenyl)-acetylamino>-N-(3-isopropoxy-4-methoxybenzyl)-3-phenylpropionamide 
• 454186-13-1 2-(4-fluoro-3-nitro-phenyl)-N-methyl-acetamide 
• 454185-89-8 [2-(4-fluoro-3-nitro-phenyl)-ethyl]-methyl-carbamic acid ethyl ester 
• 454186-14-2 3-{4-[(S)-6,7-Dimethoxy-8-(6-methoxy-2-methyl-1-oxo-1,2,3,4-tetrahydro-isoquinolin-7-yloxy)-2-methyl-1,2,3,4-tetrahydro-isoquinolin-1-ylmethyl]-phenoxy}-4-isopropoxy-benzoic acid methyl ester 
• 454185-87-6 3-[4-((S)-8-{4-[2-(Ethoxycarbonyl-methyl-amino)-ethyl]-2-methoxy-phenoxy}-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydro-isoquinolin-1-ylmethyl)-phenoxy]-4-isopropoxy-benzoic acid methyl ester 
• 454186-06-2 8-{4-[2-(ethoxycarbonyl-methyl-amino)-ethyl]-2-nitro-phenoxy}-1-[4-(2-isopropoxy-5-methoxycarbonyl-phenoxy)-benzyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 192508-38-6 <2-(4-fluoro-3-nitrophenyl)-acetylamino>-acetic acid 
• 192508-41-1 2-(4-fluoro-3-nitrophenyl)-N-<(3-hydroxy-4-methoxy-benzylcarbamoyl)-methyl>acetamide 
• 192508-40-0 2-(4-fluoro-3-nitrophenyl)-N-<(3-isopropoxy-4-methoxy-benzylcarbamoyl)-methyl>acetamide 
• 226888-40-0 2-<(2R)-2-(4-fluoro-3-nitrophenyl)-acetylamino>-N-(3-hydroxy-4-methoxybenzyl)-3-phenylpropionamide 
• 226888-37-5 4-fluoro-3-nitrophenylacetic acid methyl ester 

Relevant articles and documents

MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE

Provided are IDO inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases such as chronic viral infection, chronic bacterial infections, cancer, sepsis or a neurological disorder.

RAF INHIBITOR COMPOUNDS

This invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I); and use of a compound of Formula (I) for treating specified cancers.

SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS

The present invention relates to a series of substituted compounds having the general formula (I), including their ste reoisomers and/or their pharmaceutically acceptable salts, wherein R1, R2, R3. R4, R5, and R6 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (κ) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.

NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS

The present invention relates to novel benzimidazole derivatives of the formula (I) as defined in the description and in the claims, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAA receptor complex, and in particular for inducing and maintaining anaesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children. The compounds of the invention may also be used by veterinarians.

First enantioselective total synthesis of (-)-tejedine

(Matrix presented) The first enantioselective total synthesis of (-)-tejedine (1) is reported. Tejedine is a seco-bisbenzyltetrahydroisoquinoline isolated in 1998 as a minor component from Berberis vulgaris. The synthesis was achieved using a strategy employing four key steps, including a chiral auxiliary-assisted diastereoselective Bischler-Napieralski cyclization.

1-phenyl-benzimidazole compounds and their use as GABA-a receptor modulators

The present invention relates to novel benzimidazole compounds, represented by general formula (I) in which o is 0, 1, 2 or 3; R1represents an alkyl group, a phenyl group, or a monocyclic heterocyclic group, which groups may be substituted one or more times with substituents selected from alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, halogen, trifluoromethyl, cyano, amino and nitro; or R1represents a cyano group or a group of the formula -alkyl-CO2R2, alkenyl-CO2R2, —CO—R2, —CO2(CH2)mR2, or —C(R3)═N—OR2, R11represents a group of formula —CO2—R9, or R11represents a group of general formula (II) in which n is 0, 1, 2 or 3; or R11may represent a group of general formula (III), in which n is 0, 1, 2 or 3; the novel compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAAreceptor complex, such as for example anxiety, sleep disorders, anaestesia, memory disorders, and epilepsia or other convulsive disorders.

Synthetic studies towards western and eastern macropolypeptide subunits of Kistamycin

The western subunit (fused bicyclic 16+15 membered ring) was synthesized by sequential intramolecular S(N)Ar reaction and the first 17-membered ring compound as model of the eastern subunit was obtained by an intramolecular Ni0 mediated coupling reaction.